Multiple locations in USA, CANADA, JAPAN - 01 Dec `22A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Vitiligo

 

Official title: A phase 3 randomized, double-blind, 52-week placebo-controlled, multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo.

Brief Summary: A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Vitiligo (Active and Stable)

Detailed Description: Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo (both active and stable vitiligo).

Actual Study Start Date: December 1, 2022
Estimated Study Completion Date: June 19, 2025

Contact: Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

https://beta.clinicaltrials.gov/study/NCT05583526